An important drug candidate failed to meet its primary endpoint in a clinical trial. That left the door open for a new competitor.
News & Analysis: Sage Therapeutics
Some bad news sent several stocks sharply lower.
An important clinical trial turned in underwhelming results.
A midsize acquisition seems imminent, and these two would fit like a glove.
Earning the first FDA approval for treating postpartum depression is a big step, but it's hardly an express ticket to profit town.
SAGE earnings call for the period ending December 31, 2018.
The pharma company reported positive results from an important phase 3 trial.
These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.
These stocks skyrocketed following exciting announcements.
The tiny pharma company reported promising results in a study for its lead drug candidate, eliciting comparisons to a reputable high-flying peer.